Chilà, Rosaria <br/><br/>
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.  [electronic resource] 

 -  Oncotarget  Feb 2015 
 - 3394-408 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.2583  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Apoptosis Regulatory Proteins--genetics<br/>Benzodiazepinones--pharmacology<br/>CDC2 Protein Kinase<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Checkpoint Kinase 1<br/>Cyclin-Dependent Kinase 2--genetics<br/>Cyclin-Dependent Kinases--genetics<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Female<br/>Gene Expression Profiling<br/>Humans<br/>Inhibitory Concentration 50<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Mice, Nude<br/>Molecular Targeted Therapy<br/>Nuclear Proteins--antagonists & inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Kinases--genetics<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>Pyrimidinones<br/>Time Factors<br/>Xenograft Model Antitumor Assays